The table below summarizes the most recent Arrowhead Pharmaceuticals insider buying information, with links below the price to see the CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more information about why Arrowhead Pharmaceuticals insider buys are important for investors to follow.

Date	Insider	Price	Amount
3-20-2024 Insider Buy	Hongbo Lu Director	$27.66 CAGR »	$82,990.00 3,000 shares
12-28-2021 Insider Buy	Douglas B. Given Director	$66.37 CAGR »	$43,472.35 655 shares
10-8-2020 Insider Buy	Marianne De Backer Director	$50.47 CAGR »	$50,465.00 1,000 shares
6-15-2020 Insider Buy	Marianne De Backer Director	$33.56 CAGR »	$134,240.00 4,000 shares
10-28-2013 Insider Buy	Mauro Ferrari Director	$6.44 CAGR »	$14,808.04 2,300 shares
10-15-2014 Insider Buy	Christopher Richard Anzalone President and CEO	$6.32 CAGR »	$101,120.00 16,000 shares

Also See: Institutional Holders of ARWR
Also See: SEC filings

Below we present the annualized performance delivered by Arrowhead Pharmaceuticals stock since 3-20-2024 (the date of the most recent insider purchase). The performance of the investment from the time Arrowhead Pharmaceuticals insider buying occurred is the ultimate test of whether insiders were right about ARWR being a good buy.

Growth of $10,000.00 Without Dividends Reinvested
Start date:	03/21/2024
End date:	04/30/2024
Start price/share:	$28.23
End price/share:	$22.62
Dividends collected/share:	$0.00
Total return:	-19.87%
Annualized Gain:	-181.34%
Starting investment:	$10,000.00
Ending investment:	$8,013.00
Years:	0.11

Arrowhead Pharmaceuticals Insider Buying

This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.), and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these categories, but instead file their holdings quarterly on the latest form 13F filings. While recent Arrowhead Pharmaceuticals insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).

Also See: Funds Holding ARWR

ARWR — Current Quote

Quotes delayed 20 minutes

Free ARWR Email Alerts:
Get Dividend Alerts

Get SEC Filing Alerts

ARWR — Performance

More Insider Buying

Other companies seeing insider buying close in time to when the Arrowhead Pharmaceuticals Insider Buying occurred are:

Clough Global Opportunities Fund Insider Buying
Ovid Therapeutics Insider Buying
Heritage Global Insider Buying
Stem Insider Buying
Carriage Services Insider Buying
NextNav Insider Buying
Re/Max Holdings Insider Buying
Phillips 66 Insider Buying
Delcath Systems Insider Buying
City Office REIT Insider Buying

Arrowhead Pharmaceuticals Insider Buying | www.HoldingsChannel.com

Nothing in Holdings Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact Holdings Channel; Meet Our Editorial Staff.